Literature DB >> 16287211

Exposure-time-varying hazard function ratios in case-control studies of drug effects.

Harry A Guess1.   

Abstract

For many adverse effects of drugs, the instantaneous risk of an incident event per day of therapy (i.e., the hazard function) varies by duration of therapy and by prior exposure. In cohort studies of adverse drug effects time-varying hazard functions are easily modeled using standard statistical software packages. Tests of the hypothesis of a constant proportional hazard function ratio are also available. In case control studies, the need to consider time-varying hazard functions seems to be somewhat less well-recognized than in cohort studies. When the hazard function ratio for an adverse drug event is not constant over time, an overall single odds ratio (OR) estimated in a case control study not accounting for the time variation in the hazard function is a weighted average of duration-specific ORs with weights reflecting the distribution of exposure time in the study population. The resulting estimate depends not only on the drug but also on the exposure time distribution in the study population. This can lead to misleading conclusions when comparing the risks of two drugs within the same population and when comparing risks of the same drug in different populations. Analytic approaches for addressing time-varying hazard functions in case-control studies have been published but seem to be less used than in cohort studies. This article discusses adverse drug effects with time-varying hazard functions and methods for addressing these in case-control studies during study design, data collection, and analysis. Copyright 2005 John Wiley & Sons, Ltd.

Mesh:

Year:  2006        PMID: 16287211     DOI: 10.1002/pds.1164

Source DB:  PubMed          Journal:  Pharmacoepidemiol Drug Saf        ISSN: 1053-8569            Impact factor:   2.890


  11 in total

1.  Thiazolidinedione use and ulcerative colitis-related flares: an exploratory analysis of administrative data.

Authors:  Jennifer L Lund; Til Stürmer; Carol Q Porter; Robert S Sandler; Michael D Kappelman
Journal:  Inflamm Bowel Dis       Date:  2011-03       Impact factor: 5.325

2.  Clustering of venous thrombosis events at the start of tamoxifen therapy in breast cancer: a population-based experience.

Authors:  Adedayo A Onitilo; Suhail A R Doi; Jessica M Engel; Ingrid Glurich; John Johnson; Richard Berg
Journal:  Thromb Res       Date:  2011-12-07       Impact factor: 3.944

3.  Impact of drug interactions, dosage, and duration of therapy on the risk of hip fracture associated with benzodiazepine use in older adults.

Authors:  Kristina Zint; Walter E Haefeli; Robert J Glynn; Helen Mogun; Jerry Avorn; Til Stürmer
Journal:  Pharmacoepidemiol Drug Saf       Date:  2010-10-07       Impact factor: 2.890

4.  Misclassification in administrative claims data: quantifying the impact on treatment effect estimates.

Authors:  Michele Jonsson Funk; Suzanne N Landi
Journal:  Curr Epidemiol Rep       Date:  2014-12

5.  Adverse events associated with prolonged antibiotic use.

Authors:  Sharon B Meropol; K Arnold Chan; Zhen Chen; Jonathan A Finkelstein; Sean Hennessy; Ebbing Lautenbach; Richard Platt; Stephanie D Schech; Deborah Shatin; Joshua P Metlay
Journal:  Pharmacoepidemiol Drug Saf       Date:  2008-05       Impact factor: 2.890

6.  Vaccine Effectiveness of Polysaccharide Vaccines Against Clinical Meningitis - Niamey, Niger, June 2015.

Authors:  Marc Rondy; Djibo Issifou; Alkassoum S Ibrahim; Zaneidou Maman; Goumbi Kadade; Hamidou Omou; Sidikou Fati; Esther Kissling; Sarah Meyer; Olivier Ronveaux
Journal:  PLoS Curr       Date:  2016-04-18

Review 7.  Long-term neurodevelopmental consequences of intrauterine exposure to lithium and antipsychotics: a systematic review and meta-analysis.

Authors:  Eline M P Poels; Lisanne Schrijver; Astrid M Kamperman; Manon H J Hillegers; Witte J G Hoogendijk; Steven A Kushner; Sabine J Roza
Journal:  Eur Child Adolesc Psychiatry       Date:  2018-06-11       Impact factor: 4.785

8.  A comparison of pharmacoepidemiological study designs in medication use and traffic safety research.

Authors:  Silvia Ravera; Nienke van Rein; Johan J de Gier; Lolkje T W de Jong-van den Berg
Journal:  Eur J Epidemiol       Date:  2012-05-11       Impact factor: 8.082

9.  Bridging differences in outcomes of pharmacoepidemiological studies: design and first results of the PROTECT project.

Authors:  Victoria Abbing-Karahagopian; Xavier Kurz; Frank de Vries; Tjeerd P van Staa; Yolanda Alvarez; Ulrik Hesse; Joerg Hasford; Liset van Dijk; Francisco J de Abajo; John G Weil; Lamiae Grimaldi-Bensouda; Antoine C G Egberts; Robert F Reynolds; Olaf H Klungel
Journal:  Curr Clin Pharmacol       Date:  2014-05

10.  Risk of pneumonia with inhaled corticosteroid versus long-acting bronchodilator regimens in chronic obstructive pulmonary disease: a new-user cohort study.

Authors:  Rachael L DiSantostefano; Tim Sampson; Hoa Van Le; David Hinds; Kourtney J Davis; Nawar Diar Bakerly
Journal:  PLoS One       Date:  2014-05-30       Impact factor: 3.240

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.